N@N

Anacor Pharmaceuticals to Present at the Fifth Annual aResistance is Futile: the Challenge of Antibacterial Drug Developmenta C

^{Published on 2011-04-11 05:40:50 - Market Wire}
 

PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Dickon Alley, Ph.D., Senior Research Leader, will be presenting at the Fifth Annual aResistance is Futile: the Challenge of Antibacterial Drug Developmenta Conference hosted by Drug Discovery Chemistry in San Diego on Tuesday, April 12, 2011 at 4:30 p.m. PT. The subject of Dr. Alleya™s presentation is aTackling Microbial Resistance: Novel Targets Accessed by Boron Antibacterials.a Slides from Dr. Alleya™s presentation will be available following the presentation at [ www.anacor.com ] under News & Events.

"Tackling Microbial Resistance: Novel Targets Accessed by Boron Antibacterials."

AboutAnacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds that are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed toGlaxoSmithKlineunder the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit[ http://www.anacor.com ].